[
    [
        {
            "time": "2018-01-02",
            "original_text": "Dow Tumbles 180 Points to End Lower for the Week",
            "features": {
                "keywords": [
                    "Dow",
                    "Tumbles",
                    "Points",
                    "End",
                    "Lower",
                    "Week"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "general"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 5,
                "Market_Scope": 10,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-10-05",
            "original_text": "Johnson & Johnson Stock in the Week Ended October 5",
            "features": {
                "keywords": [
                    "Johnson",
                    "Stock",
                    "Week",
                    "Ended",
                    "October"
                ],
                "sentiment_score": 0.0,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-10-05",
            "original_text": "Market Close Report: NASDAQ Composite index closes at 7,788.45 down -91.06 points",
            "features": {
                "keywords": [
                    "NASDAQ",
                    "Composite",
                    "closes",
                    "down",
                    "points"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "technology"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-10-05",
            "original_text": "Gilead Sciences: What to Expect from the Top Line",
            "features": {
                "keywords": [
                    "Gilead",
                    "Sciences",
                    "Expect",
                    "Top",
                    "Line"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-10-05",
            "original_text": "How’s Gilead Sciences Positioned in October?",
            "features": {
                "keywords": [
                    "Gilead",
                    "Sciences",
                    "Positioned",
                    "October"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-10-05",
            "original_text": "Rising Yields Pose Risk to Large-Cap Pharma's Red-Hot Rally",
            "features": {
                "keywords": [
                    "Rising",
                    "Yields",
                    "Risk",
                    "Large-Cap",
                    "Pharma",
                    "Rally"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-10-05",
            "original_text": "Dow 30 Stock Roundup: Boeing Wins $9.2B Pilot Training Deal, Intel Keeps '18 View",
            "features": {
                "keywords": [
                    "Dow",
                    "Boeing",
                    "Wins",
                    "Pilot",
                    "Training",
                    "Deal",
                    "Intel",
                    "Keeps",
                    "'18",
                    "View"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "aerospace",
                    "technology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-10-05",
            "original_text": "Pharma Stock Roundup: PFE to Get New CEO, LLY Presents Impressive Diabetes Data",
            "features": {
                "keywords": [
                    "Pharma",
                    "Stock",
                    "Roundup",
                    "PFE",
                    "CEO",
                    "LLY",
                    "Diabetes",
                    "Data"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-10-05",
            "original_text": "Health Care Sector Update for 10/05/2018: JNJ, PFE, ABT, MRK, AMGN, HSGX, KMPH",
            "features": {
                "keywords": [
                    "Health",
                    "Care",
                    "Sector",
                    "Update",
                    "JNJ",
                    "PFE",
                    "ABT",
                    "MRK",
                    "AMGN",
                    "HSGX",
                    "KMPH"
                ],
                "sentiment_score": 0.0,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-10-05",
            "original_text": "What Seattle Genetics’ Valuation Trend Indicates",
            "features": {
                "keywords": [
                    "Seattle",
                    "Genetics",
                    "Valuation",
                    "Trend",
                    "Indicates"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 6,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-10-05",
            "original_text": "Sangamo Therapeutics: Analysts Expect 88% Upside Potential",
            "features": {
                "keywords": [
                    "Sangamo",
                    "Therapeutics",
                    "Analysts",
                    "Expect",
                    "Upside",
                    "Potential"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 6,
                "Impact": 5,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]